Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study

dc.contributor.authorUslar, Thomas
dc.contributor.authorSanfuentes, Benjamín
dc.contributor.authorOlmos, Roberto
dc.contributor.authorBurnier, Alberth
dc.contributor.authorBöhm, Pauline
dc.contributor.authorGuarda, Francisco J.
dc.contributor.authorHuete, Álvaro
dc.contributor.authorMertens, Nicolás
dc.contributor.authorBesa, Cecilia
dc.contributor.authorAndía, Marcelo
dc.contributor.authorMajerson, Alejandro
dc.contributor.authorCartes, Jaime
dc.contributor.authorTapia-Castillo, Alejandra
dc.contributor.authorCarvajal, Cristian A.
dc.contributor.authorFardella, Carlos E.
dc.contributor.authorAllende, Fidel
dc.contributor.authorSolari, Sandra
dc.contributor.authorVaidya, Anand
dc.contributor.authorBaudrand, Rene
dc.coverage.spatialNetherlands
dc.date.accessioned2026-07-21T19:35:33Z
dc.date.available2026-07-21T19:35:33Z
dc.date.issued2026-06-27
dc.description.abstractBackground: Incidental adrenal adenomas are common, yet renin status is infrequently assessed in hypertensive patients. Emerging evidence supports a spectrum of renin-independent aldosterone excess associated with adverse cardiovascular risk. Objective and methods: To determine the frequency of a low-renin phenotype in a prospective cohort of hypertensive patients with adrenal adenomas and to evaluate the clinical response to aldosterone-targeted therapy across baseline aldosterone categories. Low-renin phenotype was defined as suppressed renin (PRA <1.0 ng/mL/ h or DRC <10 μIU/mL). Among these patients, plasma aldosterone concentration (PAC) was categorized as 5–10 ng/dL (Group 1), 10–15 ng/dL (Group 2), and >15 ng/dL (Group 3). Patients with suppressed renin were treated with MR antagonists or adrenalectomy and followed longitudinally using PAMO/PASO criteria. Results: Low renin was present in 47% (138/290) of hypertensive patients. Increasing aldosterone levels were associated with higher systolic blood pressure (SBP), resistant hypertension, higher antihypertensive treatment burden, lower potassium, and reduced eGFR (p-trend <0.001). After a mean follow-up of 24±18 months (n = 121), aldosterone-targeted therapy (75% medical, 25% surgical) led to significant reductions in SBP (-18, -26, and -30 mmHg across Groups 1–3; all p < 0.001), decreased medication and significant increases in renin (all p < 0.001), irrespective of aldosterone category. Conclusions: Nearly half of hypertensive patients with adrenal incidentalomas exhibit suppressed renin levels associated with greater blood pressure burden and favorable response to aldosterone-targeted therapy, even in lower aldosterone levels categories. These findings support systematic renin assessment in hypertensive patients with incidental adrenal adenomas and provide a rationale for testing aldosterone-targeted therapy in broader hypertensive populations beyond adrenal adenomas
dc.identifier.citationEuropean Journal of Internal Medicine, (2026), Article 107042
dc.identifier.doihttps://doi.org/10.1016/j.ejim.2026.107042
dc.identifier.issn0953-6205
dc.identifier.orcidhttps://orcid.org/0000-0002-6081-1468
dc.identifier.urihttps://hdl.handle.net/20.500.12254/7674
dc.language.isoen
dc.publisherElsevier
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subjectAdrenal adenomas
dc.subjectLow renin hypertension
dc.subjectAldosterone dysregulation
dc.subjectHypertension
dc.subjectPrimary aldosteronism
dc.subjectMineralocorticoid receptor
dc.subjectAdrenal incidentaloma
dc.titleLow-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study
dc.typeArticle
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
1-s2.0-S095362052600347X-main.pdf
Tamaño:
804.88 KB
Formato:
Adobe Portable Document Format
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
347 B
Formato:
Item-specific license agreed upon to submission
Descripción: